Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Balachandran’s work could “transform the treatment of pancreatic cancer…and provide proof of concept for future cancer vaccines.”
Biden’s CUREIT initiative aims to develop a toolbox of technologies to fight cancer, autoimmune disorders and infectious diseases.
Researchers unveil a less toxic, more efficient method to genetically engineer immune cells that target tumor cells.
Researchers are working on vaccines that will target multiple flu or coronavirus strains.
Moderna and Merck’s customized neoantigen vaccine plus Keytruda lowered the risk for metastasis or death by 65%.
In a head-to-head comparison, three experimental vaccines eradicated HPV-related cancers in mice.
Experimental flu vaccine, designed to elicit immunity against a broad range of influenza viruses, performed well in a small trial.
Moderna and Merck’s personalized neoantigen vaccine plus checkpoint inhibitor lowered the risk of disease progression after surgery by 44%.
The BNT111-01 clinical trial explores an mRNA melanoma vaccine on its own and in combination with a PD-1 checkpoint immunotherapy.
Unlike custom-made vaccines, those that target common cancer antigens could be available off the shelf.
In the near future, it may be possible to design specific diets tailored to individual genomic profiles to starve tumors.
As the new editor-in-chief of Cancer Health, Trent Straube is honored to amplify stories of survivors, families, advocates and more.
The technology used to create COVID-19 vaccines may also help treat cancer.
Over the past decade, the field of mRNA therapeutics has advanced rapidly.
A vaccine designed to enhance T-cell activity could help CAR-T therapy work better against solid tumors.
Novel therapies, improved technologies and a better understanding of the immune system could yield broad dividends.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.